Novo Nordisk has agreed to pay up to $2.6 billion for the rights to an experimental once-weekly obesity pill from China's Jiangsu Hengrui Pharmaceuticals, the companies said in a news release announcing their exclusive license agreement for HRS-1596 on Sept. 29. The drug targets the same two hormone pathways as Eli Lilly's Zepbound but is designed to be swallowed once a week. It has not yet been tested in people.
For the millions of Americans considering weight-loss drugs, the deal shows where the industry is headed: fewer injections and fewer daily pills. But any weekly pill is years from pharmacy shelves, and the drugs available now are unchanged.
The agreement also shows how much large drugmakers now rely on Chinese companies for early-stage medicines. Nearly 250 GLP-1 candidates are in development in China, Reuters reported, citing data provider Pharmcube.
Terms Behind the $2.6 Billion Figure
Novo will pay $300 million upfront. The rest of the $2.6 billion depends on development, regulatory, and sales milestones that may never be reached, plus royalties on any future sales. Novo gets exclusive rights everywhere except mainland China, Hong Kong, Macao, and Taiwan, where Hengrui keeps control.
HRS-1596 activates receptors for both GLP-1 and GIP, gut hormones that affect appetite and blood sugar. Hengrui has received approval in China to begin phase 1 trials for weight management and type 2 diabetes. The deal is expected to close in the fourth quarter of 2026, pending U.S. antitrust clearance and other standard conditions.
Martin Holst Lange, Novo's chief scientific officer, said the company is "excited to add HRS-1596 to our growing pipeline and to explore its potential to raise the bar for convenience in the field." Frank Jiang, Hengrui's chief strategy officer, said, "Together, we aim to advance this innovative therapy for patients worldwide."
Novo's Push to Regain Ground
The deal comes as Novo tries to recover from losing market share to Lilly. Its shares have fallen more than 70% from their record high, Reuters reported, and several of its patents expire within the next decade. It is Novo's second licensing deal since its investor day the prior week, STAT reported, following an agreement with Swedish drug delivery company Nanexa for technology that could allow obesity injections every few months.
Chief Executive Mike Doustdar has said the company "felt strongly that we needed to make some radical changes" to adjust to a "radically changed environment," Fierce Biotech reported. According to Reuters, Doustdar is preparing Novo for a market in which pills play a much larger role.
The pill market is already crowded. The FDA approved Novo's daily Wegovy pill in December 2025 and Lilly's daily Foundayo in April 2026. Viking Therapeutics is testing a daily GLP-1/GIP tablet in phase 2, according to Fierce Biotech.
The GLP-1/GIP combination is the same approach behind tirzepatide, the active ingredient in Zepbound and Mounjaro. The oral GLP-1 drugs approved so far are taken daily. The companies have not released data showing how long HRS-1596 stays active in the body, so once-weekly dosing remains a goal rather than a proven feature.
Analysts See a Long Road Ahead
The deal drew a cautious response from some analysts. BMO Capital Markets, which kept its Market Perform rating on Novo, called it "not the transformative agreement some market participants may have anticipated," Investing.com reported. BMO said "HRS-1596 remains in early development and the deal is unlikely to alter near-term competitive dynamics," and noted that the early-stage risk is reflected in the deal's financial terms.
Markus Manns, a portfolio manager at Union Investment, told Reuters the deal was positive for Novo but that the company needs larger deals for more advanced drugs to change how the market views it.
Hengrui has become a frequent partner for Western companies. It has struck licensing deals with GSK and Bristol Myers Squibb, and its obesity portfolio helped Kailera Therapeutics raise a record $625 million in an April initial public offering, Fierce Biotech reported. AstraZeneca, Merck, and Pfizer have also licensed rights from Chinese GLP-1 developers, according to Reuters.
Patients Weighing Current Weight-Loss Options
A weekly pill could someday help people who dislike injections but struggle to remember a daily tablet. Still, HRS-1596 must pass phase 1 safety testing, then larger trials measuring weight loss and side effects, before the FDA could review it. That process usually takes many years, and most early-stage drugs never reach approval.
Nothing in this deal is a reason to delay or change current treatment. People interested in weight-loss medicine can ask a clinician which approved options fit their health history, whether a daily pill or weekly injection better suits their routine, and what side effects to expect. Stomach upset is common with this drug class, and severe abdominal pain that does not go away needs prompt medical attention.
Cost often matters more than convenience. Many insurers still exclude weight-loss drugs, and cash prices vary by product and dose, so patients should check coverage and manufacturer savings programs before filling a prescription. Buying unapproved or compounded versions from unverified sellers carries safety risks.
More competition in obesity drugs has already pushed makers to offer lower cash prices on some products, and new entrants could add pressure over time. Whether that happens with HRS-1596 depends on trial results, approvals, and pricing decisions that have not been made.
The next milestones are the deal's expected closing later this year and the start of human testing. Patients may not see results for years, but the deal is one more sign that the next generation of obesity drugs is being built around convenience.
Key Questions Answered
What did Novo Nordisk buy?
Rights outside mainland China, Hong Kong, Macao, and Taiwan to HRS-1596, Hengrui's experimental once-weekly GLP-1/GIP pill, for up to $2.6 billion, including $300 million upfront.
Is the pill available?
No. It has been cleared to start phase 1 trials in China but has not yet been tested in people.
How is it different from current pills?
The Wegovy pill and Foundayo are taken daily. HRS-1596 is designed for once-weekly dosing, though that has not been shown in people.
What do analysts say?
BMO called the deal not transformative and said it is unlikely to change near-term competition, while a Union Investment portfolio manager called it positive but said Novo needs larger deals for more advanced drugs.
Why are companies turning to China?
Chinese developers have a large number of early obesity candidates, and several large drugmakers have licensed rights from them.
Should I wait for a weekly pill?
No. Talk with a clinician about approved options now. Any weekly pill is likely years away.
Published by Medicaldaily.com
